Fig. 1From: Infliximab for treatment-refractory transverse myelitis following immune therapy and radiationCoronal positron emission tomography images of patient before (a) and 5 months after (b) initiation of ICI demonstrating complete resolution of widespread hypermetabolic lesions in the lungs, liver, skeleton and mediastinum with the exception of a residual lesion in the left ischiumBack to article page